Evidence map›Paper›PMID 33240421›Full record

ArticleOncology letters2021

Elena Lastraioli, Lorenzo Antonuzzo, Beatrice Fantechi, Luisa Di Cerbo, Alessandro Di Costanzo, Daniele Lavacchi, Miriam Armenio, Annarosa Arcangeli, Francesca Castiglione, Luca Messerini and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Evaluation ofCells · 2023
    Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Elena LastraioliDepartment of Experimental and Clinical Medicine, University of Florence, I-50134 Florence, Italy.
Lorenzo AntonuzzoMedical Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, I-50134 Florence, Italy.
Beatrice FantechiMedical Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, I-50134 Florence, Italy.
Luisa Di CerboMedical Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, I-50134 Florence, Italy.
Alessandro Di CostanzoMedical Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, I-50134 Florence, Italy.
Daniele LavacchiMedical Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, I-50134 Florence, Italy.
Miriam ArmenioDepartment of Experimental and Clinical Medicine, University of Florence, I-50134 Florence, Italy.
Annarosa ArcangeliDepartment of Experimental and Clinical Medicine, University of Florence, I-50134 Florence, Italy.
Francesca CastiglioneSection of Pathological Anatomy, Department of Health Sciences, University of Florence, Azienda Ospedaliero-Universitaria Careggi, I-50134 Florence, Italy.
Luca MesseriniDepartment of Experimental and Clinical Medicine, University of Florence, I-50134 Florence, Italy.
Francesco Di CostanzoMedical Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, I-50134 Florence, Italy.
Azienda Ospedaliero-Universitaria Careggi · ITUniversity of Florence · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with metastatic colorectal cancer (mCRC) are routinely screened for either

Indexed as

beadsemulsions amplificationKRASmagneticsmass spectrometrymetastatic colorectal cancerNRAS

Identifiers

PMID33240421
PMCPMC7681220
OpenAlexW3097569156

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.